跳至主要内容
临床试验/NCT00612027
NCT00612027已完成不适用

Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions

AstraZeneca0 个研究点目标入组 29,586 人开始时间: 2006年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
29,586
主要终点
efficacy and tolerability of esomeprazole in patients who are treated by general practitioners and internists

研究概览

简要总结

Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. general practitioners and internists) are asked to document relevant data related to esomeprazole therapy in patients with gastrointestinal disorders. Patients with acid associated gastrointestinal symptoms can be included.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole.

排除标准

  • limitiations; possible risks; warnings; contraindications mentioned in the SPC.

结局指标

主要结局

efficacy and tolerability of esomeprazole in patients who are treated by general practitioners and internists

时间窗: proportion of treated subjects without any specific acid associated symptoms at the end of the study; change in intensity of specific acid associated symptoms; incidence of the occurrence of unknown, unexpected and/or rarely occurring adverse events AE.

次要结局

  • evaluation of a diagnosis tool(evaluation of the predictive value of a two items questionnaire on acid associated symptoms)

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验